Targeted drugs for chronic lymphocytic leukemia include ibrutinib and AMG319 (PI3K inhibitor). Patients with chronic lymphocytic leukemia have abnormal activation of BTK, PI3K and other molecular signaling pathways in their cells, and specific inhibitors against the above signaling pathways may become targeted drugs for the treatment of chronic lymphocytic leukemia. 1. Ibrutinib: At present, Ibrutinib, a specific inhibitor of BTK pathway, has become the first-line drug for patients with chronic lymphocytic leukemia. The response rate of single-agent Ibrutinib in the first-line treatment of chronic lymphocytic leukemia can reach 90%, and the number of patients who have achieved complete remission can reach 11%. 2.AMG319: It mainly targets the inhibition of PI3K pathway, thus treating chronic lymphocytic leukemia. If the diagnosis of chronic lymphocytic leukemia is confirmed, standardized treatment should be carried out under the guidance of specialists, avoiding self-medication.